Evidence map›Paper›PMID 31633999›Full record

ArticleJCO clinical cancer informatics2019

Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes.

Gian Maria Zaccaria, Simone Ferrero, Samanta Rosati, Marco Ghislieri, Elisa Genuardi, Andrea Evangelista, Rebecca Sandrone, Cristina Castagneri, Daniela Barbero, Mariella Lo Schirico and 10 more

Registry-linked trialAbstract read
In one paragraph

Article in JCO clinical cancer informatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02354313 (A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02354313 phase3unknown statusnot on this map

A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma

TypeinterventionalSponsorFondazione Italiana Linfomi - ETSRan2010 to 2019Enrolled300ConditionsMANTLE CELL LYMPHOMAArmsLenalidomide
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Gian Maria ZaccariaUniversità di Torino, Turin, Italy.
Simone FerreroUniversità di Torino, Turin, Italy.
Samanta RosatiPolitecnico di Torino, Turin, Italy.
Marco GhislieriPolitecnico di Torino, Turin, Italy.
Elisa GenuardiUniversità di Torino, Turin, Italy.
Andrea EvangelistaUnit of Clinical Epidemiology, Centro di Prevenzione Oncologica (CPO), Città della Salute e della Scienza di Torino, Hospital of Turin, Turin, Italy.
Rebecca SandronePolitecnico di Torino, Turin, Italy.
Cristina CastagneriPolitecnico di Torino, Turin, Italy.
Daniela BarberoUniversità di Torino, Turin, Italy.
Mariella Lo SchiricoUniversity of Padua, Padua, Italy.
Luca ArcainiFondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Policlinico San Matteo, University of Pavia, Pavia, Italy.
Anna Lia MolinariInfermi Hospital, Rimini, Italy.
Filippo BalleriniUniversity of Genoa, Ospedale Policlinico San Martino, IRCCS per l'Oncologia, Genoa, Italy.
Andres FerreriIRCCS San Raffaele Scientific Institute, Milan, Italy.
Paola OmedèUniversità di Torino, Turin, Italy.
Alberto ZamòUniversità di Torino, Turin, Italy.
Gabriella BalestraPolitecnico di Torino, Turin, Italy.
Mario BoccadoroUniversità di Torino, Turin, Italy.
Sergio CortelazzoOncology Unit Clinica Humanitas/Gavazzeni, Bergamo, Italy.
Marco LadettoDivision of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeData collection in clinical trials is becoming complex, with a huge number of variables that need to be recorded, verified, and analyzed to effectively measure clinical outcomes. In this study, we used data warehouse (DW) concepts to achieve this goal. A DW was developed to accommodate data from a large clinical trial, including all the characteristics collected. We present the results related to baseline variables with the following objectives: developing a data quality (DQ) control strategy and improving outcome analysis according to the clinical trial primary end points.

methodsData were retrieved from the electronic case reporting forms (eCRFs) of the phase III, multicenter MCL0208 trial (ClinicalTrials.gov identifier: NCT02354313) of the Fondazione Italiana Linfomi for younger patients with untreated mantle cell lymphoma (MCL). The DW was created with a relational database management system. Recommended DQ dimensions were observed to monitor the activity of each site to handle DQ management during patient follow-up. The DQ management was applied to clinically relevant parameters that predicted progression-free survival to assess its impact.

resultsThe DW encompassed 16 tables, which included 226 variables for 300 patients and 199,500 items of data. The tool allowed cross-comparison analysis and detected some incongruities in eCRFs, prompting queries to clinical centers. This had an impact on clinical end points, as the DQ control strategy was able to improve the prognostic stratification according to single parameters, such as tumor infiltration by flow cytometry, and even using established prognosticators, such as the MCL International Prognostic Index.

conclusionThe DW is a powerful tool to organize results from large phase III clinical trials and to effectively improve DQ through the application of effective engineered tools.

Indexed as

AgedClinical Trials, Phase III as TopicData WarehousingDisease ProgressionFemaleHumansLymphoma, Mantle-CellMaleMulticenter Studies as TopicNeoplasm StagingQuality Assurance, Health CareRandomized Controlled Trials as TopicSurvival RateTreatment Outcome

Identifiers

PMID31633999
PMCPMC6873907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.